Beyond Air, Inc. Stock

Equities

XAIR

US08862L1035

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 12:02:11 2024-05-09 pm EDT 5-day change 1st Jan Change
1.255 USD -2.71% Intraday chart for Beyond Air, Inc. +4.92% -34.69%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.44M Sales 2025 * 13.2M Capitalization 59.21M
Net income 2024 * -62M Net income 2025 * -64M EV / Sales 2024 * 32.7 x
Net cash position 2024 * 12.15M Net Debt 2025 * 2.95M EV / Sales 2025 * 4.71 x
P/E ratio 2024 *
-0.67 x
P/E ratio 2025 *
-0.74 x
Employees 98
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.02%
More Fundamentals * Assessed data
Dynamic Chart
1 week+14.16%
Current month+19.44%
1 month-19.88%
3 months-25.86%
6 months-35.50%
Current year-34.18%
More quotes
1 week
1.16
Extreme 1.16
1.39
1 month
1.06
Extreme 1.06
1.67
Current year
1.06
Extreme 1.06
2.17
1 year
1.06
Extreme 1.06
6.36
3 years
1.06
Extreme 1.06
16.41
5 years
1.06
Extreme 1.06
16.41
10 years
1.06
Extreme 1.06
16.41
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-01-12
Director of Finance/CFO 53 21-08-31
President 50 17-01-12
Members of the board TitleAgeSince
Director/Board Member 58 15-07-31
Director/Board Member 62 18-08-12
Director/Board Member 57 17-08-09
More insiders
Date Price Change Volume
24-05-09 1.28 -0.78% 62 454
24-05-08 1.29 0.00% 381,785
24-05-07 1.29 +2.79% 340,501
24-05-06 1.255 -3.46% 667,287
24-05-03 1.3 +6.56% 327,247

Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT

More quotes
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.29 USD
Average target price
12.6 USD
Spread / Average Target
+876.74%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW